2,802 results match your criteria Cardiovascular drugs and therapy[Journal]


Correction to: Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.

Cardiovasc Drugs Ther 2020 Jul 1. Epub 2020 Jul 1.

Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30.001, Groningen, 9700, RB, The Netherlands.

MI surgery increased the myocardial expression of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) and increased the relative expression of foetal (β-MHC) compared to with that of adult (α-MHC) myosin heavy-chain isoform (i.e. β-MHC/α-MHC ratio). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07029-2DOI Listing

Can Clinical and Functional Outcomes Be Improved with an Intelligent "Internet Plus"-Based Full Disease Cycle Remote Ischemic Conditioning Program in Acute ST-elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention? Rationale and Design of the i-RIC Trial.

Cardiovasc Drugs Ther 2020 Jun 30. Epub 2020 Jun 30.

Department of Rehabilitation Medicine, The First Affiliated Hospital of Nanjing Medical University, No.300 Guangzhou Road, Nanjing, 210029, China.

Background: Acute ST-elevation myocardial infarction (STEMI) is associated with a high incidence of complications as well as a considerable hospitalization rate and economic burden. Preliminary evidence suggests that remote ischemic conditioning (RIC) is a promising non-invasive intervention that may effectively and safely reduce myocardial infarct size, subsequent cardiac events and complications, and mortality. However, RIC's cardio-protective effect remains under debate, especially for single timepoint RIC programs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07022-9DOI Listing

Benefit-Risk Profile of DAPT Continuation Beyond 1 Year after PCI in Patients with High Thrombotic Risk Features as Endorsed by 2018 ESC/EACTS Myocardial Revascularization Guideline.

Cardiovasc Drugs Ther 2020 Jun 29. Epub 2020 Jun 29.

Department of Cardiology, Coronary Heart Disease Center, Fuwai Hospital, State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100037, China.

Purpose: The ischemic/bleeding trade-off of continuing dual antiplatelet therapy (DAPT) beyond 1 year after PCI for patients with high thrombotic risk (HTR) as endorsed by 2018 ESC/EACTS myocardial revascularization guidelines remain unknown.

Methods: Patients undergoing coronary stenting between January 2013 and December 2013 from the prospective Fuwai registry were defined as HTR if they met at least 1 ESC/EACTS guideline-endorsed HTR criteria. A total of 4578 patients who were at HTR and were events free at 1 year after the index procedure were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07030-9DOI Listing
June 2020
3.189 Impact Factor

Patient Characteristics and Treatment Patterns among Medicare Beneficiaries Initiating PCSK9 Inhibitor Therapy.

Cardiovasc Drugs Ther 2020 Jun 27. Epub 2020 Jun 27.

Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington Street, Box 063, Boston, MA, 02111, USA.

Purpose: There is limited real-world evidence around use of proprotein convertase subtilisin-kexin type 9 inhibitors (PCSK9i) among US older adults. This study examined baseline characteristics of fee-for-service (FFS) Medicare beneficiaries newly initiating PCSK9i therapy during the period immediately following market availability.

Methods: This cross-sectional study used Medicare claims (2013-2016) to identify 5051 FFS Medicare beneficiaries who filled ≥ 1 PCSK9i prescription between August 2015 and December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07028-3DOI Listing

Impact of PRECISE-DAPT and DAPT Scores on Dual Antiplatelet Therapy Duration After 2nd Generation Drug-Eluting Stent Implantation.

Cardiovasc Drugs Ther 2020 Jun 25. Epub 2020 Jun 25.

Severance Cardiovascular Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, South Korea.

Purpose: Determining the optimal duration of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation is an important clinical issue. We evaluated the effects of ischemia (by DAPT score) and bleeding (by PRECISE-DAPT score), as well as the impact of DAPT duration, on clinical outcomes.

Methods: From pooled analysis of four randomized clinical trials, 5131 patients undergoing second-generation DES implantation were randomized to short-duration (n = 2575; ≤ 6 months) or standard-duration (n = 2556; ≥ 12 months) DAPT groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07008-7DOI Listing

CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.

Cardiovasc Drugs Ther 2020 Jun 24. Epub 2020 Jun 24.

Department of Cardiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, 510080, Guangdong, People's Republic of China.

Background: Heart failure (HF) patients have high risks of thromboembolic events regardless of the category of left ventricular ejection fraction. We sought to assess whether the CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke, vascular disease, age 65-74 years, and female sex) and ATRIA (anticoagulation and risk factors in atrial fibrillation) scores could predict clinical outcomes in HF patients with preserved ejection fraction (HFpEF).

Methods: We performed a retrospective analysis in a multicenter, America-based population of 1766 HFpEF patients who were stratified according to their baseline CHA2DS2-VASc or ATRIA scores. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07011-yDOI Listing

Ticagrelor Versus Clopidogrel in Patients with Late or Very Late Stent Thrombosis.

Cardiovasc Drugs Ther 2020 Jun 22. Epub 2020 Jun 22.

Department of Coronary Heart Disease Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Purpose: To compare the effect of ticagrelor with clopidogrel in reducing the risk of ischemic cardiovascular events in patients with late or very late stent thrombosis (LST/VLST) after primary percutaneous coronary intervention (PCI).

Methods: A total of 4538 patients with acute coronary syndrome were screened for angiographically determined LST/VLST. Two hundred and forty-one patients were included in the analysis and grouped according to ticagrelor (n = 81) or clopidogrel (n = 160) at discharge. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07021-wDOI Listing

Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence.

Authors:
Leonardo De Luca

Cardiovasc Drugs Ther 2020 Jun 20. Epub 2020 Jun 20.

Department of Cardiosciences, Division of Cardiology, A.O. San Camillo Forlanini, Circonvallazione Gianicolense, 87, 00152, Rome, Italy.

After an episode of myocardial infarction (MI), patients remain at risk for recurrent ischemic events, heart failure (HF), and sudden death. Post-MI patients with left ventricular systolic dysfunction (LVSD) have an even greater risk of mortality and morbidity. Randomized clinical trials that included post-MI patients with LVSD have demonstrated that pharmacologic therapies aimed at preventing post-MI remodeling with neurohormonal antagonists can significantly improve short- and long-term outcomes, including death, reinfarction, and worsening HF. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07027-4DOI Listing

Diallyl Trisulfide Suppresses Angiotensin II-Induced Vascular Remodeling Via Inhibition of Mitochondrial Fission.

Cardiovasc Drugs Ther 2020 Jun 20. Epub 2020 Jun 20.

Department of Cardiology, The Second Hospital of Shanxi Medical University, 382 Wuyi Road, Taiyuan, 030001, Shanxi, China.

Objective: We have shown previously that diallyl trisulfide (DATS) ameliorates mitochondrial fission and oxidative stress in a hyperglycemia-induced endothelial apoptosis and diabetic mouse model. The aim of this study was to investigate whether DATS mitigates Ang II-induced vascular smooth muscle cell (VSMC) phenotypic switching and vascular remodeling, and if so, to determine the underlying molecular events.

Methods: Male C57BL/6 mice were used to establish a vascular remodeling model by continuous 2-week Ang II infusion using a subcutaneous osmotic pump. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07000-1DOI Listing

Smooth Muscle Sirtuin 1 Blocks Thoracic Aortic Aneurysm/Dissection Development in Mice.

Cardiovasc Drugs Ther 2020 Jun 20. Epub 2020 Jun 20.

Department of Cardiology, China-Japan Friendship Hospital, Beijing, China.

Purpose: Advancing age is the major risk factor for thoracic aortic aneurysm/dissection (TAAD). However, the causative link between age-related molecules and TAAD remains elusive. Here, we investigated the role of Sirtuin 1 (SIRT1, also known as class III histone deacetylase), the best studied member of the longevity-related Sirtuin family, in TAAD development in vivo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07005-wDOI Listing

Pralidoxime-Induced Potentiation of the Pressor Effect of Adrenaline and Hastened Successful Resuscitation by Pralidoxime in a Porcine Cardiac Arrest Model.

Cardiovasc Drugs Ther 2020 Jun 19. Epub 2020 Jun 19.

Department of Emergency Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea.

Purpose: Pralidoxime potentiated the pressor effect of adrenaline and facilitated restoration of spontaneous circulation (ROSC) after prolonged cardiac arrest. In this study, we hypothesised that pralidoxime would hasten ROSC in a model with a short duration of untreated ventricular fibrillation (VF). We also hypothesised that potentiation of the pressor effect of adrenaline by pralidoxime would not be accompanied by worsening of the adverse effects of adrenaline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07026-5DOI Listing

Idebenone Protects against Atherosclerosis in Apolipoprotein E-Deficient Mice Via Activation of the SIRT3-SOD2-mtROS Pathway.

Cardiovasc Drugs Ther 2020 Jun 17. Epub 2020 Jun 17.

Department of Neurology and Research Institute of Neuromuscular and Neurodegenerative Diseases, Qilu Hospital, Shandong University, Jinan, 25000, Shandong, China.

Purpose: Atherosclerosis, a chronic disease of the arteries, results from pathological processes including the accumulation and aggregation of oxidized low-density lipoprotein (oxLDL) in the vessel walls, development of neointima, formation of a fibrous cap, and migration of immune cells to damaged vascular endothelium. Recent studies have shown that mitochondrial dysfunction is closely associated with the development and progression of atherosclerosis. Idebenone, a short-chain benzoquinone similar in structure to coenzyme Q10, can effectively clear oxygen free radicals as an electron carrier and antioxidant. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07018-5DOI Listing

A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.

Cardiovasc Drugs Ther 2020 Jun 17. Epub 2020 Jun 17.

Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07024-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7297930PMC

Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.

Cardiovasc Drugs Ther 2020 Jun 18. Epub 2020 Jun 18.

Albany Medical College and Albany Medical Center, Albany, NY, USA.

Atherosclerotic cardiovascular disease (ASCVD) remains an important contributor of morbidity and mortality in patients with chronic kidney disease (CKD). CKD is recognized as an important risk enhancer that identifies patients as candidates for more intensive low-density lipoprotein (LDL) cholesterol lowering. However, there is controversy regarding the efficacy of lipid-lowering therapy, especially in patients on dialysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07020-xDOI Listing

Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR).

Cardiovasc Drugs Ther 2020 Jun 16. Epub 2020 Jun 16.

National Amyloidosis Centre, Division of Medicine, UCL Medical School, Royal Free Hospital, Rowland Hill Street, NW3 2PF, London, UK.

The original article contained incorrect terminology for one of the cardiac measures; throughout the manuscript and supplementary information 'intraventricular septum wall thickness' should have been given as 'interventricular septum wall thickness'. Corrections should also be noted for Tables 1 and 4: in the Table 1 legend 'Low risk - Neither above at baseline' should read 'Low risk - Neither above threshold at baseline'; in Table 4, the rows 'Mild: eGFR > 60 to < 90 ml/min/1.73 m' and 'Moderate: eGFR > 30 to < 60 ml/min/1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07023-8DOI Listing

The Impairment in Kidney Function in the Oral Anticoagulation Era. A Pathophysiological Insight.

Cardiovasc Drugs Ther 2020 Jun 13. Epub 2020 Jun 13.

Cardiology Department, University of Bari, Bari, Italy.

The need for anticoagulation in patients with atrial fibrillation (AF) is fundamental to prevent thromboembolic events. Direct oral anticoagulants (DOACs) recently demonstrated to be superior, or at least equal, to Warfarin in reducing the risk for stroke/systemic embolism and preventing major bleeding and intracranial hemorrhages. The AF population often suffers from chronic kidney disease (CKD). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07004-xDOI Listing
June 2020
3.189 Impact Factor

Biotechnology Approaches for the Treatment of Dyslipidemia.

Authors:
Cinzia Parolini

Cardiovasc Drugs Ther 2020 Jun 9. Epub 2020 Jun 9.

Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, via Balzaretti, 9, 20133, Milan, Italy.

Background: Despite advances in the development of lipid-lowering therapies, clinical trials have shown that a significant residual risk of cardiovascular disease persists. Specifically, new drugs are needed for non-responding or statin-intolerant subjects or patients considered at very high risk for cardiovascular events even though are already on treatment with the best standard of care.

Results And Conclusions: Besides, genetic and epidemiological studies and Mendelian randomization analyses have strengthened the linear correlation between the concentration of low-density lipoprotein cholesterol (LDL-C) and the incidence of cardiovascular events and highlighted various novel therapeutic targets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07017-6DOI Listing

Angiotensin Receptor Neprilysin Inhibitors-2019 Update.

Cardiovasc Drugs Ther 2020 Jun 9. Epub 2020 Jun 9.

Cardiology Department, Medical School, Democritus University of Thrace, Dragana, 68100, Alexandroupolis, Greece.

An abundance of new data regarding the use of the novel drug compound sacubitril/valsartan in chronic heart failure (CHF) patients is published every year since the initial publication of the PARADIGM-HF study in 2014. This review summarises the most recent evidence (2019 and onwards) of sacubitril/valsartan in CHF patients as well as provides a critical appraisal of these data. New data are grouped in categories such as real-world data, randomised controlled trials, surrogate end-points, cost-effectiveness, use of sacubitril/valsartan as an anti-hypertensive treatment, effect on diuretic dosing and implementation of this novel compound in other populations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07015-8DOI Listing

Research Progress on the Involvement of ANGPTL4 and Loss-of-Function Variants in Lipid Metabolism and Coronary Heart Disease: Is the "Prime Time" of ANGPTL4-Targeted Therapy for Coronary Heart Disease Approaching?

Cardiovasc Drugs Ther 2020 Jun 4. Epub 2020 Jun 4.

Department of Cardiology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410000, Hunan, China.

Background: Multiple genetic studies have confirmed the definitive link among the loss-of-function variants of angiogenin-like protein 4 (ANGPTL4), significantly decreased plasma triglyceride (TG) levels, and reduced risk of coronary heart disease (CHD). The potential therapeutic effect of ANGPTL4 on dyslipidemia and CHD has been widely studied.

Objective: This review provides a detailed introduction to the research progress on the involvement of ANGPTL4 in lipid metabolism and atherosclerosis and evaluates the efficacy and safety of ANGPTL4 as a therapeutic target for CHD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07001-0DOI Listing

Ultrasound Theranostics in Adult and Pediatric Cardiovascular Research.

Cardiovasc Drugs Ther 2020 Jun 3. Epub 2020 Jun 3.

The Helen B. Taussig Heart Center, The Johns Hopkins Hospital, The Johns Hopkins University School of Medicine, M2315, 1800 Orleans St, Baltimore, MD, 21287, USA.

Theranostics, the practice of systematically integrating diagnostics with treatment, has evolved as a field of medicine. In the context of ultrasound based theranostics, both traditional microbubbles and inorganic nanoparticles have emerged as technologies of clinical interest. Ultrasound induced microbubble cavitation has demonstrated efficacy in a variety of applications, including thrombolysis, tumor ablation, targeted microvascular flow enhancement, and targeted drug and gene delivery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07016-7DOI Listing

TAK1-AMPK Pathway in Macrophages Regulates Hypothyroid Atherosclerosis.

Cardiovasc Drugs Ther 2020 Jun 3. Epub 2020 Jun 3.

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, No.2, Anzhen Road, Chaoyang District, Beijing, 100029, China.

Purpose: Hypothyroidism (HT) is associated with accelerated atherosclerosis (AS). The efficacy of traditional strategies of hypothyroid AS remains controversial. Here, we aimed to deepen the understanding of the HT-induced acceleration of AS, to decrease the residual risk of coronary artery disease (CAD) and to find a new therapeutic target. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06996-wDOI Listing

Aspirin Discontinuation in Patients Requiring Oral Anticoagulation Undergoing Percutaneous Coronary Intervention, The Role of Procedural Complexity.

Cardiovasc Drugs Ther 2020 Jun 2. Epub 2020 Jun 2.

Cardiology Department, Royal Victoria Hospital, Belfast, UK.

Background: The prognostic role of procedural complexity when discontinuing aspirin in patients on oral anticoagulation undergoing percutaneous coronary intervention (PCI) has never been studied.

Methods: Ischaemic events were compared in 256 consecutive patients according to procedural complexity and aspirin on discharge. PCI complexity was defined according to the high-risk features for ischaemic events in the current guidelines RESULTS: Forty percent patients had stable presentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07012-xDOI Listing

Vasopressin in Patients with Septic Shock and Dynamic Left Ventricular Outflow Tract Obstruction.

Cardiovasc Drugs Ther 2020 Jun 2. Epub 2020 Jun 2.

Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, Unit of Anaesthesia and Intensive Care Fondazione Policlinico San Matteo, IRCCS, University of Pavia, Pavia, Italy.

Purpose: Left ventricular outflow tract obstruction (LVOTO) is a relatively uncommon but severe condition that may lead to hemodynamic impairment. It can be elicited by morphological (left ventricular hypertrophy, sigmoid septum, prominent papillary muscle, prolonged anterior mitral valve leaflet) and functional (hypovolemia, low afterload, hypercontractility, catecholamines) factors. We sought to determine the incidence of the most severe form of LVOTO in septic shock patients and describe the therapeutic effects of vasopressin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06998-8DOI Listing

Exendin-4 Attenuates Remodeling in the Remote Myocardium of Rats After an Acute Myocardial Infarction by Activating β-Arrestin-2, Protein Phosphatase 2A, and Glycogen Synthase Kinase-3 and Inhibiting β-Catenin.

Cardiovasc Drugs Ther 2020 May 30. Epub 2020 May 30.

Department of Clinical Cardiology, College of Medicine, King Khalid University, Abha, Saudi Arabia.

Purpose: This study tested if the protective anti-remodeling effect of GLP-1 agonist Exendin-4 after an acute myocardial infarction (MI) in rats involves inhibition of the Wnt1/β-catenin signaling pathway.

Methods: Rats were divided into sham, sham + Exendin-4 (10 μg/day, i.p), MI, and MI + Exendin-4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07006-9DOI Listing

Tailoring Dual Antiplatelet Therapy for the Complex PCI Patient: Current Status and Perspectives.

Cardiovasc Drugs Ther 2020 May 29. Epub 2020 May 29.

2nd Department of Cardiology, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Rimini 1, Chaidari, 12462, Athens, Greece.

Dual antiplatelet therapy (DAPT) duration in patients undergoing percutaneous coronary intervention (PCI) has long been considered a matter of controversy. Complex-PCI (C-PCI) is considered to be associated with an increased ischemic risk that tends to be greater with progressively higher procedural complexity. Thus, with a view to balance ischemic versus bleeding risks, high complexity of PCI intuitively represents an advocate of prolonged DAPT duration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07009-6DOI Listing

CD38: A Potential Therapeutic Target in Cardiovascular Disease.

Cardiovasc Drugs Ther 2020 May 29. Epub 2020 May 29.

Department of Cardiovascular Medicine, The Second Xiangya Hospital of Central South University, No. 139 Middle Renmin Road, Furong District, Changsha, 410011, Hunan, China.

Substantial research has demonstrated the association between cardiovascular disease and the dysregulation of intracellular calcium, ageing, reduction in nicotinamide adenine dinucleotide NAD+ content, and decrease in sirtuin activity. CD38, which comprises the soluble type, type II, and type III, is the main NADase in mammals. This molecule catalyses the production of cyclic adenosine diphosphate ribose (cADPR), nicotinic acid adenine dinucleotide phosphate (NAADP), and adenosine diphosphate ribose (ADPR), which stimulate the release of Ca, accompanied by NAD+ consumption and decreased sirtuin activity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07007-8DOI Listing

Attenuation of atrial remodeling by aliskiren via affecting oxidative stress, inflammation and PI3K/Akt signaling pathway.

Cardiovasc Drugs Ther 2020 May 27. Epub 2020 May 27.

Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin, 300211, China.

Introduction: Atrial fibrillation (AF) is the most common type of arrhythmia. Atrial remodeling is a major factor to the AF substrate. The purpose of the study is to explore whether aliskiren (ALS) has a cardioprotective effect and its potential molecular mechanisms on atrial remodeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-07002-zDOI Listing

Mitochondrial Oxidative Phosphorylation Function and Mitophagy in Ischaemic/Reperfused Hearts from Control and High-Fat Diet Rats: Effects of Long-Term Melatonin Treatment.

Cardiovasc Drugs Ther 2020 May 26. Epub 2020 May 26.

Division of Medical Physiology, Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, University of Stellenbosch, PO Box 241, Cape Town, 8000, South Africa.

Purpose: Oxidative stress causes mitochondrial dysfunction in myocardial ischaemia/reperfusion (I/R) as well as in obesity. Mitochondrial depolarization triggers mitophagy to degrade damaged mitochondria, a process important for quality control. The aims of this study were to evaluate (i) the effect of I/R on mitochondrial oxidative phosphorylation and its temporal relationship with mitophagy in hearts from obese rats and their age-matched controls, and (ii) the role of oxidative stress in these processes using melatonin, a free radical scavenger. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06997-9DOI Listing

Factor Xa Inhibition with Apixaban Does Not Influence Cardiac Remodelling in Rats with Heart Failure After Myocardial Infarction.

Cardiovasc Drugs Ther 2020 May 26. Epub 2020 May 26.

Department of Cardiology, University Medical Center Groningen, University of Groningen, PO Box 30.001, Groningen, 9700 RB, The Netherlands.

Background: Heart failure (HF) is considered to be a prothrombotic condition and it has been suggested that coagulation factors contribute to maladaptive cardiac remodelling via activation of the protease-activated receptor 1 (PAR1). We tested the hypothesis that anticoagulation with the factor Xa (FXa) inhibitor apixaban would ameliorate cardiac remodelling in rats with HF after myocardial infarction (MI).

Methods And Results: Male Sprague-Dawley rats were either subjected to permanent ligation of the left ascending coronary artery (MI) or sham surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06999-7DOI Listing

A TOR2A Gene Product: Salusin-β Contributes to Attenuated Vasodilatation of Spontaneously Hypertensive Rats.

Cardiovasc Drugs Ther 2020 May 26. Epub 2020 May 26.

Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center of Translational Medicine for Cardiovascular Disease, Nanjing Medical University, Nanjing, 211166, Jiangsu, China.

Purpose: Attenuated vasodilatation of small arteries is a hallmark feature of hypertension. Salusin-β, which is a TOR2A gene product and an important vasoactive peptide, has a close relationship with cardiovascular disease. This study aimed to determinate the roles of salusin-β in vasodilatation, and its signal pathways in Wistar-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06983-1DOI Listing

Protection of Sacubitril/Valsartan against Pathological Cardiac Remodeling by Inhibiting the NLRP3 Inflammasome after Relief of Pressure Overload in Mice.

Cardiovasc Drugs Ther 2020 May 23. Epub 2020 May 23.

Department of Cardiology, Zhejiang provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, 310014, China.

Background/aims: The persistent existence of pathological cardiac remodeling, resulting from aortic stenosis, is related to poor clinical prognosis after successful transcatheter aortic valve replacement (TAVR). Sacubitril/valsartan (Sac/Val), comprising an angiotensin receptor blocker and a neprilysin inhibitor, has been demonstrated to have a beneficial effect against pathological cardiac remodeling, including cardiac fibrosis and inflammation in heart failure. The aim of this study was to determine whether Sac/Val exerts a cardioprotective effect after pressure unloading in mice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06995-xDOI Listing
May 2020
3.189 Impact Factor

"BAX602" in Preventing Surgical Adhesion after Extracorporeal Ventricular Assist Device Implantation for Refractory Congestive Heart Failure: Study Protocol for a Multicenter Randomized Clinical Trial.

Cardiovasc Drugs Ther 2020 May 22. Epub 2020 May 22.

Department of Cardiac Surgery, National Cerebral and Cardiovascular Center, 6-1 Kishibeshimmachi, Suita, Osaka, 564-8565, Japan.

Background: The high surgical risk in redo cardiac surgery is largely attributed to adhesions around the epicardium and the great vessels. BAX602 is an adhesion prevention reagent composed of two synthetic polyethylene glycols. Spraying BAX602 over the epicardium and the great vessels reportedly contributes to adhesion prevention after pediatric cardiac surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06990-2DOI Listing

The Clinical Role of Angiopoietin-Like Protein 3 in Evaluating Coronary Artery Disease in Patients with Obstructive Sleep Apnea.

Cardiovasc Drugs Ther 2020 May 21. Epub 2020 May 21.

Key Laboratory of Upper Airway Dysfunction-related Cardiovascular Diseases, Beijing An Zhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Beijing, 100029, China.

Purpose: Hyperlipidemia is the most important early atherosclerosis and coronary artery disease (CAD) indicator. Angiopoietin-like proteins (ANGPTLs) 3, 4, and 8 are lipid dysfunction markers that may be linked to CAD. We investigated whether these circulating ANGPTLs are associated with CAD in patients with obstructive sleep apnea (OSA). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06991-1DOI Listing

CTRP15 derived from cardiac myocytes attenuates TGFβ1-induced fibrotic response in cardiac fibroblasts.

Cardiovasc Drugs Ther 2020 May 19. Epub 2020 May 19.

Department of Physiology and Pathophysiology, Peking University School of Basic Medical Sciences; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing, 100191, China.

Purpose: Cardiac fibrosis is characterized by net accumulation of extracellular matrix (ECM) components in the  myocardium and facilitates the development of heart failure. C1q/tumor necrosis factor-related protein 15 (CTRP15) is a novel member of the CTRP family, and its gene expression is detected in adult mouse hearts. The present study was performed to determine the effect of CTRP15 on pressure overload-induced fibrotic remodeling. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06970-6DOI Listing
May 2020
3.189 Impact Factor

Empagliflozin Protects Cardiac Mitochondrial Fatty Acid Metabolism in a Mouse Model of Diet-Induced Lipid Overload.

Cardiovasc Drugs Ther 2020 May 19. Epub 2020 May 19.

Latvian Institute of Organic Synthesis, Aizkraukles 21, Riga, 1006, Latvia.

Purpose: Sodium-glucose cotransporter 2 (SGLT2) inhibitors prevent heart failure and decrease cardiovascular mortality in patients with type 2 diabetes. Heart failure is associated with detrimental changes in energy metabolism, and the preservation of cardiac mitochondrial function is crucial for the failing heart. However, to date, there are no data to support the hypothesis that treatment with a SGLT2 inhibitor might alter mitochondrial bioenergetics in diabetic failing hearts. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06989-9DOI Listing

Major Cardiac-Psychiatric Drug-Drug Interactions: a Systematic Review of the Consistency of Drug Databases.

Cardiovasc Drugs Ther 2020 May 19. Epub 2020 May 19.

Faculty of Medicine, University of Ottawa, Ottawa, Canada.

Purpose: Major depressive disorder (MDD) and anxiety disorders (AD) are both highly prevalent among individuals with arrhythmia, ischemic heart disease, heart failure, hypertension, and dyslipidemia. There should be increased support for MDD and AD diagnosis and treatment in individuals with cardiac diseases, because treatment rates have been low. However, cardiac-psychiatric drug interaction can make pharmacologic treatment challenging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06979-xDOI Listing

Inpatient Initiation of Oral Treprostinil in an Academic Medical System.

Cardiovasc Drugs Ther 2020 Aug;34(4):547-553

Department of Pharmacy, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH, 44095, USA.

Purpose: Clinicians may transition patients on parenteral or inhaled prostacyclins to oral treprostinil for ease of use or to avoid adverse effects related to parenteral therapy. However, few data are available to guide these transitions in inpatients. The purpose of this analysis is to describe the inpatient initiation of oral treprostinil at an academic medical system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06992-0DOI Listing

Single-Strand DNA-Like Oligonucleotide Aptamer Against Proprotein Convertase Subtilisin/Kexin 9 Using CE-SELEX: PCSK9 Targeting Selection.

Cardiovasc Drugs Ther 2020 Aug;34(4):475-485

Department of Molecular Biology and Genetics, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, 8174673461, Iran.

Background: Proprotein convertase subtilisin/kexin 9 (PCSK9) serves a key regulatory function in the metabolism of low-density lipoprotein (LDL)-cholesterol (LDL-C) through interaction with the LDL receptor (LDLR) followed by its destruction that results in the elevation of the plasma levels of LDL-C. The aims of the present study were to separate and select a number of single-stranded DNA (ssDNA) aptamers against PCSK9 from a library pool (n > 10) followed by their characterization.

Methods: The aptamers obtained from the DNA-PCSK9 complexes which presented the highest affinity against PCSK9 were separated and selected using capillary electrophoresis evolution of ligands by exponential enrichment (CE-SELEX). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06986-yDOI Listing

Artificial Intelligence Uncovered Clinical Factors for Cardiovascular Events in Myocardial Infarction Patients with Glucose Intolerance.

Cardiovasc Drugs Ther 2020 Aug;34(4):535-545

Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, 6-1 Kishibe-Shimmachi, Suita, Osaka, Japan.

Purpose: Glucose intolerance (GI), defined as either prediabetes or diabetes, promotes cardiovascular events in patients with myocardial infarction (MI). Using the pooled clinical data from patients with MI and GI in the completed ABC and PPAR trials, we aimed to identify their clinical risk factors for cardiovascular events.

Methods: Using the limitless-arity multiple testing procedure, an artificial intelligence (AI)-based data mining method, we analyzed 415,328 combinations of < 4 clinical parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06987-xDOI Listing

Berberine Attenuates Cardiac Hypertrophy Through Inhibition of mTOR Signaling Pathway.

Cardiovasc Drugs Ther 2020 Aug;34(4):463-473

Guangzhou Institute of Cardiovascular Disease, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, China.

Purpose: Berberine was reported to exert beneficial effects on cardiac hypertrophy. However, its cellular and molecular mechanisms still remained unclear.

Methods: Cardiac hypertrophy was induced in male Sprague-Dawley (SD) rats by transverse aorta constriction (TAC), with or without 6-week treatment of berberine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06977-zDOI Listing

Efficacy and Safety of Inorganic Nitrate Versus Placebo Treatment in Heart Failure with Preserved Ejection Fraction.

Cardiovasc Drugs Ther 2020 Aug;34(4):503-513

Department of Cardiology, The Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, 410000, Hunan, China.

Background: Heart failure with preserved ejection fraction (HFpEF) is common, yet there is a lack of effective treatments. In this meta-analysis, we assessed the efficacy and safety of inorganic nitrate in patients with HFpEF.

Methods And Results: We systematically searched PubMed, Embase, and the Cochrane Library from the inception of the database through March 2020. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06980-4DOI Listing
August 2020
3.189 Impact Factor

A Call for Vaccine Against COVID-19: Implications for Cardiovascular Morbidity and Healthcare Utilization.

Cardiovasc Drugs Ther 2020 Aug;34(4):585-587

Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06985-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206411PMC

Titin and CK2α are New Intracellular Targets in Acute Insulin Application-Associated Benefits on Electrophysiological Parameters of Left Ventricular Cardiomyocytes From Insulin-Resistant Metabolic Syndrome Rats.

Cardiovasc Drugs Ther 2020 Aug;34(4):487-501

Department of Biophysics, Faculty of Medicine, Ankara University, Ankara, Turkey.

Background: Previous studies have demonstrated that a high-carbohydrate intake could induce metabolic syndrome (MetS) in male rats with marked cardiac functional abnormalities. In addition, studies mentioned some benefits of insulin application on these complications, but there are considerable disagreements among their findings. Therefore, we aimed to extend our knowledge on the in-vitro influence of insulin on left ventricular dysfunction and also in the isolated cardiomyocytes from MetS rats. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06974-2DOI Listing

Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study.

Cardiovasc Drugs Ther 2020 Aug;34(4):515-523

Lipid Clinic, Point Médical and Department of Cardiology, CHU Dijon-Bourgogne, Dijon, France.

Purpose: During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical trials with alirocumab. This post hoc analysis evaluated the differences in physician-patient dosing decisions between the regions of Western Europe, Eastern Europe, North America, and the rest of the world (ROW).

Methods: Patients (n = 909) who received starting dose alirocumab 75 mg every 2 weeks (Q2W) during ODYSSEY OLE (patients from FH I, FH II, and LONG TERM parent studies) were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06984-0DOI Listing

Sodium-Glucose Co-transporter 2 Inhibitors in the Failing Heart: a Growing Potential.

Cardiovasc Drugs Ther 2020 Jun;34(3):419-436

Heart Failure Clinic, Hospital São Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal.

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are a new drug class designed to treat patients with type 2 diabetes (T2D). However, cardiovascular outcome trials showed that SGLT2i also offer protection against heart failure (HF)-related events and cardiovascular mortality. These benefits appear to be independent of glycaemic control and have recently been demonstrated in the HF population with reduced ejection fraction (HFrEF), with or without T2D. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06973-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242490PMC

Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients.

Cardiovasc Drugs Ther 2020 Aug;34(4):555-568

Department of Cardiology and Angiology, Hannover Medical School, Carl-Neuberg-Str. 1, D-30659, Hannover, Germany.

Ischaemic stroke and systemic embolism are the major potentially preventable complications of atrial fibrillation (AF) leading to severe morbidity and mortality. Anticoagulation using vitamin K antagonists (VKA) or non-vitamin K oral anticoagulants (NOACs) is mandatory for stroke prevention in AF. Following approval of the four NOACs dabigatran, rivaroxaban, apixaban, and edoxaban, the use of VKA is declining steadily. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06981-3DOI Listing
August 2020
3.189 Impact Factor

Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay.

Cardiovasc Drugs Ther 2020 Aug;34(4):443-461

The Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, 301 University Blvd, BSB 648, Galveston, TX, 77555, USA.

Purpose: Ticagrelor, a P2Y12 receptor antagonist, and dapagliflozin, a sodium-glucose-cotransporter-2 inhibitor, suppress the activation of the NLRP3 inflammasome. The anti-inflammatory effects of dapagliflozin depend on AMPK activation. Also, ticagrelor can activate AMPK. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06978-yDOI Listing

Reflections of the Angiotensin Receptor Blocker Recall by the FDA and Repercussions on Healthcare.

Cardiovasc Drugs Ther 2020 Aug;34(4):579-584

Section of Cardiology, Baylor College of Medicine and the Michael DeBakey VA Medical Center, 2002 Holcombe Blvd (111), Houston, TX, 77030, USA.

Purpose: Beginning in July of 2018, the FDA issued a voluntary recall regarding the presence of a contaminant found in the manufacturing of valsartan. What would ensue has become a largely unprecedented sequence of alarming events since the FDA began reporting public recalls, withdrawals and safety alerts on their website in 2016. Since then, the United States has been significantly impacted by drug recalls affecting angiotensin receptor blockers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06976-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171054PMC

Ibutilide Reduces Ventricular Defibrillation Threshold and Organizes Ventricular Fibrillation Activation in Canine Heart Failure Model.

Cardiovasc Drugs Ther 2020 Jun;34(3):323-334

Department of Cardiology, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, No. 197, Ruijin Er Road, Shanghai, 200025, China.

Purpose: To compare the effects of class III antiarrhythmic agents (amiodarone vs. ibutilide) on ventricular fibrillation (VF) and hemodynamic status in a canine heart failure (HF) model.

Methods: A total of 12 beagles were used to establish the HF model by rapid pacing for 4 consecutive weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10557-020-06958-2DOI Listing